Welcome to our comprehensive resource on Small Intestinal Bacterial Overgrowth (SIBO) and Irritable Bowel Syndrome (IBS), where we delve into the latest clinical research studies conducted by renowned experts in the field. If you are seeking credible and science-backed information about these complex gastrointestinal conditions, you've come to the right place.

At the Good LFE, we are dedicated to providing you with a wealth of knowledge about SIBO, IBS, and other gut health disorders that affect millions of individuals worldwide. Our aim is to empower and educate individuals who have been formally diagnosed with SIBO, as well as those who suspect they may be grappling with this condition.

Dr. Mark Pimentel and Dr. Ali Rezaie are internationally recognized experts in the study and treatment of SIBO and IBS. Their groundbreaking research has not only contributed to a deeper understanding of these conditions but has also revolutionized the diagnostic and therapeutic approaches employed by healthcare professionals. By featuring their work, we ensure that you have access to the most up-to-date and authoritative information available.
Navigating the vast landscape of SIBO and IBS can be overwhelming, and we understand the challenges you may face in your quest for answers. We have carefully curated this collection of research studies to provide you with a comprehensive understanding of these conditions, encompassing their causes, symptoms, diagnostic methods, treatment options, and ongoing advancements in the field. Our intention is to empower you with knowledge, enabling you to make informed decisions about your health and work collaboratively with your healthcare provider.

Featured Clinical Research

AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review

Journal of the American Gastroenterological Association (AGA) | Eamonn M.M. Quigley, Joseph A. Murray, Mark Pimentel

Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth (SIBO) is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal symptoms and is increasingly implicated in lay press and media in the causation of a diverse array of disorders. Its definition, however, remains controversial and true prevalence, accordingly, undefined. The purpose of this review, therefore, was to provide a historical background to the concept of SIBO, critically review current concepts of SIBO (including symptomatology, pathophysiology, clinical consequences, diagnosis and treatment), define unanswered questions and provide a road map toward their resolution.

Additional Research

The American Journal of Gastroenterology | Ali Rezaie, MD, MSc, FRCP(C)1, Michelle Buresi, MD, Anthony Lembo, MD, Henry Lin, MD, Richard McCallum, MD, Satish Rao, MD, Max Schmulson, MD, Miguel Valdovinos, MD, Salam Zakko, MD, and Mark Pimentel, MD, FRCP(C)1, on behalf of The North American Consensus group on hydrogen and methane-based breath testing

This study aimed to develop a new patient-reported outcome (PRO) instrument called the Small Intestinal Bacterial Overgrowth (SIBO) Symptom Measure (SSM) to assess symptom severity in patients with SIBO. SIBO is a condition characterized by an overgrowth of bacteria in the small intestine, leading to various symptoms and a negative impact on patients' quality of life.

The study involved three stages. In the first stage, a literature review and interviews with clinicians and SIBO patients were conducted to identify the symptoms important to patients. This information was used to draft the initial version of the SSM. In the second stage, additional patient interviews were conducted to refine the SSM and test its effectiveness. The draft SSM was revised based on patient feedback, and cognitive interviews were conducted iteratively to improve the instrument. In the third stage, further cognitive interviews were conducted to confirm the content validity of the SSM and ensure its appropriateness for patients.

The study identified 15 relevant symptoms during the initial stage, which were narrowed down to 11 items for inclusion in the final SSM. The symptoms assessed by the SSM include bloating, abdominal distention, abdominal discomfort, abdominal pain, flatulence, physical tiredness, nausea, diarrhea, constipation, appetite loss, and belching.

Overall, the study provided evidence supporting the content validity of the SSM as a well-defined measure of SIBO symptoms. The instrument is now ready for further validation studies to evaluate its psychometric properties.

The development of the SSM is important because there is currently no disease-specific PRO measure for SIBO that assesses symptom burden and meets the requirements of the US Food and Drug Administration (FDA). The SSM aims to address this gap and provide a reliable and valid tool for assessing symptom severity in clinical trials with SIBO patients.


The American Journal of Gastroenterology | Mark Pimentel, M.D., Evelyn J Chow, B.A., Henry C Lin, M.D.

Irritable bowel syndrome is the most common gastrointestinal diagnosis. The symptoms of irritable bowel syndrome are similar to those of small intestinal bacterial overgrowth. The purpose of this study was to test whether overgrowth is associated with irritable bowel syndrome and whether treatment of overgrowth reduces their intestinal complaints. This study concluded that small intestinal bacterial overgrowth is associated with irritable bowel syndrome. Eradication of the overgrowth eliminated irritable bowel syndrome by study criteria in 48% of subjects.


Use this text to share information about your brand with your customers. Describe a product, share announcements, or welcome customers to your store.